Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15337536 | 0.90 | NR1I2 (0.35) | NR1I2RXRAGRIN1GRIN2B | |
| SCHEMBL17708173 | 0.88 | — | — | |
| SCHEMBL15786420 | 0.87 | NR1I2 (0.31) | NR1I2RXRAGRIN1GRIN2B | |
| SCHEMBL17708407 | 0.82 | BACE1 (0.32) | NR1I2ADRA1DADRA1AADRA1BRXRA | |
| SCHEMBL15337640 | 0.82 | GAA (0.32) | NR1I2RXRAGRIN1GRIN2B | |
| SCHEMBL15786421 | 0.82 | NR1I2 (0.34) | NR1I2 | |
| SCHEMBL15337539 | 0.81 | KCNN4 (0.38) | NR1I2RXRAGRIN1GRIN2B | |
| SCHEMBL15337291 | 0.81 | P2RX7 (0.35) | NR1I2RXRAGRIN1GRIN2B | |
| SCHEMBL17708380 | 0.81 | DHODH (0.33) | NR1I2 | |
| SCHEMBL15337556 | 0.81 | RXRA (0.33) | NR1I2RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-9321763-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | NR1I2 4347/4885ADRA1D 4456/4885ADRA1A 4331/4885 |
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | NR1I2 4347/4885ADRA1D 4456/4885ADRA1A 4331/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | NR1I2 4347/4885ADRA1D 4456/4885ADRA1A 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.